Breaking Life Sciences (3 book series) October 1, 2026 | Ross Youngs The definitive trilogy that turns the invisible chemistry of life into measurable power, the right speed of innovation into a controllable system, and closed-loop biology into humanity’s next operating system. Most organizations are still flying blind. They pour billions into drug discovery while R&D productivity collapses under Eroom’s
LC-MS/MS Strategy Using Substructure Searching for the Annotation of Cyanopeptide Classes: Implications for New Compound Discovery and Environmental Monitoring June 20, 2026 | Runjie Xia, Lindsey Ahn, Michaela Burkhauser, Ross Youngs, Matthew J. Bertin* Abstract Cyanobacterial harmful algal blooms (cyanoHABs) are a major ecological and public health concern, commonly monitored for hepatotoxic microcystins and cylindrospermopsins and neurotoxic anatoxins and saxitoxins.
PITCH GLOBAL in SAN DIEGO on June 22 June 08, 2026 | By Ross Youngs Ross Youngs, CEO of Biosortia, will be at BIO in San Diego all week and will be presenting at Pitch Global. Let’s discuss how our Grounded Exclusive Biological DATA supercharges Biosortia’s discovery engine. Ask anyone — It’s about the DATA. What can Biosortia’s 13-stage AI
Biosortia and Ross Youngs Announce Appointment of Jaime Streator to Board of Directors April 07, 2026 | By Biosortia COLUMBUS, OH, UNITED STATES, April 7, 2026 /EINPresswire.com/ — Biosortia and Founder, Ross Youngs today announced the appointment of Jaime Streator to their Board of Directors, Mr. Streator brings over four decades of deep experience in healthcare investment banking to the board, further strengthening the organizations’ strategic
Pharmaceuticals from marine sources: past, present and future An overview of why marine natural products are an attractive prospect for future drug discovery, including history of the field, successes in the clinic and challenges associated with gaining clinical approval.
